CTL019 Out of Specification MAP for ALL or DLBCL Patients
a study on Acute Lymphoblastic Leukemia Leukemia Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma
Summary
- Location
- at San Francisco, California and other locations
- Dates
- study started
Description
Summary
Managed Access Program (MAP) to provide access to CTL019, for acute lymphoblastic leukemia (ALL) or diffuse large b-cell lymphoma (DLBCL) patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release.
Official Title
Managed Access Program (MAP) to Provide Access to CTL019, for ALL or DLBCL Patients With Out of Specification Leukapheresis Product and/or Manufactured Tisagenlecleucel Out of Specification for Commercial Release
Details
The purpose of this Managed Access Program (MAP) Treatment Plan is to provide access to CTL019, for acute lymphoblastic leukemia (ALL) or diffuse large b-cell lymphoma (DLBCL) patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release where no overwhelming safety concerns has been identified for manufacture and release of the out of specification product.
Keywords
Acute Lymphoblastic Leukemia (ALL) Diffuse Large B-cell Lymphoma (DLBCL) Acute Lymphoblastic Leukemia ALL Pediatric Diffuse Large b-cell Lymphoma DLBCL Adult Relapse Refractory CTL019 tisagenlecleucel Kymriah CART19 CART CAR T cells Chimeric antigen receptor Manufacturing Expanded Access Out of Specification Precursor Cell Lymphoblastic Leukemia-Lymphoma Leukemia, Lymphoid Lymphoma, B-Cell Lymphoma, Large B-Cell, Diffuse
Eligibility
You can join if…
- Written informed consent must be obtained prior to any screening procedures or treatment assignment.
- Has a patient specific batch of CTL019 which is out of specification either due to out of specification incoming apheresis or final product not meeting commercial release.
- Not excluded from commercial manufacturing under the prescribing guidelines for their country
- Out of specification material has not been deemed to pose an undue safety risk to the patient
- Is suffering from a serious or life-threatening disease or condition
- Repeat leukapheresis is not feasible per the treating physician assessment
- Does not have access to a comparable or satisfactory alternative treatment
- Is not eligible for participation in any of the IMP's ongoing clinical trials or has recently completed a clinical trial that has been terminated and, after considering other options, the clinical team has determined that treatment is necessary and there are no other feasible alternatives for the patient
- Meets any other relevant medical criteria for compassionate use of the investigational product
- Is not being transferred from an ongoing clinical trial for which they are still eligible
You CAN'T join if...
- Product can be commercially manufactured per the specification of the country in which treatment will occur.
- Patients who are able to repeat leukapheresis.
- Evidence of CD19 negative disease
- HIV positive patients
- Patients with active replication of Hep B or active or latent Hep C
- History of hypersensitivity to any drugs or metabolites of similar chemical classes as tisagenlecleucel.
- Uncontrolled active infection or inflammation
- History of unstable angina or MI within 6 months prior to screening
- Any medical condition identified by the investigator that may impact the assessment of the safety or efficacy outcomes in relation to study treatment
Locations
- UCSF
not accepting new patients
San Francisco California 94143 United States - Stanford, Lucile Packard Children's Hospital
not accepting new patients
Palo Alto California 94304 United States - Stanford
not accepting new patients
Palo Alto California 94304 United States - Stanford Healthcare
not accepting new patients
Stanford California 94305 United States - Medical City Dallas Texas
not accepting new patients
Dallas Texas 57230 United States
Details
- Status
- not accepting new patients
- Start Date
- Sponsor
- Novartis Pharmaceuticals
- ID
- NCT03601442
- Study Type
- Expanded Access
- Last Updated
Frequently Asked Questions
Please contact me about this study
We will not share your information with anyone other than the team in charge of this study. Submitting your contact information does not obligate you to participate in research.
Thank you!
The study team should get back to you in a few business days.
You will also receive an email with next steps. Check your junk/spam folder if needed.
If you do not hear from the study team, please call 888-689-8273 and tell them you’re interested in study number NCT03601442.